Sandra De Meyer - Concepedia

Author

Sandra De Meyer

Also Known As

Meyer, S., S De Meyer, S Meyer, S de Meyer, S. De Meyer, S. Meyer, S. de Meyer, Sandra De Meyer, Sandra Meyer, Sandra de Meyer

151

Publications

Citations

H-Index

Concepts

All Affiliations

Janssen (Belgium)Janssen (United States)Goethe University Frankfurt Justus-Liebig-Universität Gießen Vertex Pharmaceuticals (United States)

About

Sandra De Meyer is an author at Janssen (Belgium) specializing in medicine, immunology, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	21	1.2K
2	Health Sciences	4	4	136
3	Biochemistry	3	3	371
4	Natural Sciences	2	2	327
5	Public Health	1	1	15

Sandra De Meyer

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Telaprevir for Retreatment of HCV Infection Stefan Zeuzem, Pietro Andreoné, Stanislas Pol, New England Journal of Medicine	2011	1.5K
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 Roberto Ortiz, Edwin DeJesus, Homayoon Khanlou, AIDS	2008	382
TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates Sandra De Meyer, Hilde Azijn, Dominique Surleraux, Antimicrobial Agents and Chemotherapy Broad RangeProtease InhibitorAntiviral ActivityMedicineHiv-1 Lai	2005	354
Discovery and Selection of TMC114, a Next Generation HIV-1 Protease Inhibitor Dominique Surleraux, Abdellah Tahri, Wim G. Verschueren, Journal of Medicinal Chemistry ImmunologyMolecular BiologyAntiviral DrugViral Structural ProteinChemical Biology	2004	255
Short-Time Infusion of Fish Oil-Based Lipid Emulsions, Approved for Parenteral Nutrition, Reduces Monocyte Proinflammatory Cytokine Generation and Adhesive Interaction with Endothelium in Humans Konstantin Mayer, Sandra De Meyer, Marion Reinholz-Muhly, The Journal of Immunology	2003	190
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials James C. Sullivan, Sandra De Meyer, Doug J. Bartels, Clinical Infectious Diseases	2013	164
Resistance Profile of Darunavir: Combined 24-Week Results from the POWER Trials Sandra De Meyer, Tony Vangeneugden, Ben Van Baelen, AIDS Research and Human Retroviruses	2008	157
Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment Doug J. Bartels, James C. Sullivan, Eileen Z. Zhang, Journal of Virology	2012	144
Lack of antiviral activity of darunavir against SARS-CoV-2 Sandra De Meyer, Denisa Bojková, Jindřich Činátl, International Journal of Infectious Diseases	2020	136
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies Oliver Lenz, Thierry Verbinnen, Bart Fevery, Journal of Hepatology	2014	131

Page 1